WAVE Life Sciences' Cash And Cash Equivalents Of $200M As Of December 31, 2023; Additional $34M Received In 1Q 2024 In A Milestone Payment From GSK And Net Proceeds From Full Exercise Of Greenshoe Option, With Runway Expected Into 4Q 2025
Benzinga Newsdesk - Mar 6, 2024, 7:34AM